Patients from throughout New York City, the United States, and around the world come to the Meyer Cancer Treatment Center at Weill Cornell Medical College (WCMC) and NewYork-Presbyterian (NYP) for treatment of lymphoma. We have developed an outstanding team (including medical oncologists, hematologists, transplant physicians, radiation oncologists, surgeons, radiologists and pathologists), nurses and related health care professionals in order to care for people living with lymphoma. Our experience with current treatments, cutting edge therapies, and clinical trials is important to patients whether they are in need of frontline therapy or treatment for relapsed/refractory lymphoma.
The clinical care that is our top priority is informed and augmented by our research and teaching capacities. While our clinicians are recognized as national and international leaders in the lymphoma field, we also collaborate with the world-class scientists at WCMC and around the world, bringing the latest advances from the laboratory to the bedside through clinical trials. We are not content to only provide patient care for people currently living with lymphoma, but also seek out medical advances that will potentially alleviate the suffering of people diagnosed with lymphoma in the future.
In practice, our treatment has a substantial focus on therapy through clinical trials. We have a broad portfolio of clinical trials for Hodgkin lymphoma and virtually every subtype of non-Hodgkin lymphoma, including Chronic lymphocytic leukemia/small lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, Waldenstrom’s Macroglobulinemia. We have been involved in and contributed to the development of the vast majority of FDA approved lymphoid cancer therapies and are continually conducting clinical trials with the most promising novel agents.
More information about our program and the wider field of lymphoma can be found on our blog. Physicians interested in making referrals for a second opinion or a clinical trials can contact us directly. We also encourage you to sign up for our quarterly e-newsletter to receive the latest news regarding advances in lymphoma treatment, research and clinical trials.